low-molecular-weight heparin


Also found in: Dictionary, Wikipedia.

low-molecular-weight heparin (LMWH)

a class of drugs used to prevent potentially fatal blood clots in patients undergoing surgery or patients at risk for blood clots. It has been used to prevent deep vein thrombosis in patients undergoing hip and knee replacements. LMWH has an advantage over regular heparin in that predictable plasma levels are achieved, obviating the need for regular monitoring of prothrombin time and partial thromboplastin time.
References in periodicals archive ?
CLOT refers to the Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT).
Low-molecular-weight heparin should be the drug of choice for the initial treatment of deep vein thrombosis in cancer patients, according to new management recommendations developed by the National Comprehensive Cancer Network.
Patients with factor V Leiden mutations who've received low-molecular-weight heparin within 12 hours of labor onset should take a heparin test before undergoing neuraxial anesthesia.
The primary objective of the study is to assess the predictive value of the ENOX test to measure the whole blood anticoagulant effect of the low-molecular-weight heparin enoxaparin relative to ischemic and hemorrhagic outcomes associated with PCI.
1 selling low-molecular-weight heparin in the world, Lovenox(R) is obtained by alkaline degradation of heparin benzyl ester and is about one-third the molecular size of unfractionated heparin.
NEW ORLEANS -- Antithrombotic treatment, in the form of the low-molecular-weight heparin reviparin, has been shown for the first time to safely improve outcomes after acute myocardial infarction.
Aventis, which manufactures the low-molecular-weight heparin (LMWH), sent a letter to health care professionals in February about additions to the drug's labeling information.
The patient responded to corticosteroids, low-molecular-weight heparin, clindamycin, and azathioprine therapy, they said.
Outpatient management with a low-molecular-weight heparin is the wave of the future for treating deep vein thrombosis.
With 1999 worldwide sales exceeding $780 million, enoxaparin is the number-one selling low-molecular-weight heparin (LMWH) in the world.
1-selling low-molecular-weight heparin in the world, Lovenox(R) was approved in the United States and Canada in 1993.

Full browser ?